2008
A TWO-YEAR STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF TARANABANT IN OBESE PATIENTS: 52 WEEK RESULTS
Carr R, Gantz I, Erondu N, Moreno M, Suryawanshi S, Musser B, Nayee J, Johnson-Levonas A, Heymsfield S, Amatruda J. A TWO-YEAR STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF TARANABANT IN OBESE PATIENTS: 52 WEEK RESULTS. Atherosclerosis Plus 2008, 9: 12. DOI: 10.1016/s1567-5688(08)70044-8.Peer-Reviewed Original ResearchEFFECTS OF TARANABANT, A NOVEL CANNABINOID 1 RECEPTOR (CB-1R) INVERSE AGONIST, ON WEIGHT REDUCTION IN OBESE PATIENTS OVER 12 WEEKS
Carr R, Erondu N, Gonzalez C, Gumbiner B, Musser B, Lu K, Capece R, Klein S, Ravussin E, Amatruda J, Heymsfield S. EFFECTS OF TARANABANT, A NOVEL CANNABINOID 1 RECEPTOR (CB-1R) INVERSE AGONIST, ON WEIGHT REDUCTION IN OBESE PATIENTS OVER 12 WEEKS. Atherosclerosis Plus 2008, 9: 209. DOI: 10.1016/s1567-5688(08)70835-3.Peer-Reviewed Original Research
1989
Insulin and steatonecrosis: Are they related?
Amatruda J, Salhanick A. Insulin and steatonecrosis: Are they related? Hepatology 1989, 10: 1024-1025. PMID: 2684837, DOI: 10.1002/hep.1840100627.Peer-Reviewed Original ResearchConceptsFree fatty acidsIntraperitoneal insulinInsulin secretionAdipose tissueType II diabetes mellitusMarked weight lossPeritoneal dialysis patientsSetting of obesityNon-alcoholic individualsPathogenesis of steatosisConcentrations of insulinType II diabetesJejunoileal bypassObese patientsRenal failureDiabetes mellitusDialysis patientsCAPD patientsHepatic histologyPresence of insulinFFA mobilizationHepatic steatosisIntraperitoneal administrationPortal veinInsulin concentrations
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply